A review discussing BPC 157 as a potential treatment for COVID-19 echoes similar issues with available data surrounding BPC 157, but does note that BPC 157 has been proven to be efficacious and safe in clinical trials evaluating its use for inflammatory bowel disease (mild to moderate ulcerative colitis)
This means every vial has been compounded under pharmaceutical-grade conditions, tested for sterility and potency, prepared specifically for human administration under a valid prescription, and tracked from source to patient
Exported mainly to main markets in Asia, Africa, and Europe, delivery time is typically prompt, meeting global demand standards
5-Amino-1MQ is studied in metabolic research
, Beiram, R
Unlike many peptides, BPC 157 is unique due to its remarkable stability and widespread cytoprotective properties